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ENDOTHELIAL  FUNCTION 
Oral L-Arginine Inhibits Platelet Aggregation but Does Not Enhance 
Endothelium-Dependent Dilation in Healthy Young Men 
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JACQUI  ROBINSON,  RN,* DAVID S. CELERMAJER,  PHD, FRACP*t  
Sydney, New South Wales, Australia 
Objectives. Our aim was to assess the effect of oral L-arginine on 
endothelial or platelet physiology in humans. 
Background. L-Arginine is the substrate for nitric oxide synthe- 
sis, and in cholesterol-fed rabbits, oral L-arginine improves endo- 
thelium-dependent dilation, i hibits platelet aggregation and 
reduces atberoma. In hypercholesterolemic humans, intravenous 
L.arginine immediately improves endothelium-dependent dila- 
tion; however, the vascular effects of oral L-arginine in healthy 
humans have not previously been investigated. 
Methods. In a prospective, double-blind, randomized crossover 
trial, 12 healthy young men 27 to 37 years old took L-arginine (7 g 
three times daily) or placebo for 3 days each, separated by a 
washout period of 7 to 14 days. 
Results. After L-arginine, plasma levels of arginine (mean -+ 
SEM 303 --- 36 vs. 128 -+ 12 pmol/liter, p = 0.01) and urea (6.7 -+ 
0.5 vs. 5.2 + 0.2 mmol/liter, p < 0.01) were higher than levels 
measured after placebo, and platelet aggregation in response to 
adenosine diphosphate was markedly impaired (37 -+ 12% vs. 
81 + 3%, p = 0.02). The inhibition of platelet aggregation 
correlated with the plasma level of L-arginine (r = 0.74, p = 0.01), 
and it could be completely or partially reversed by ex vivo 
incubation with N.monomethyl-L-arginine, a specific nitric oxide 
synthase inhibitor. Platelet cyclic guanosine monophosphate l v- 
els were higher after oral L-arginine than at baseline (1.91 -+ 0.46 
vs. 1.38 _+ 0.40 pmol/109 platelets, p = 0.04). No changes were seen 
in fasting lipid levels, heart rote, blood pressure, endothelium- 
dependent dilation of the brochial artery (measured in response to 
reactive hyperemia, using external vascular ultrasound) (6.1 ± 0.7%
vs. 6.5 -+ 0.7%, p = NS) or in plasma levels of nitrosylated proteins 
(a marker of in vivo nitric oxide production) (3.5 -+ 0.5 vs. 3.3 -+ 
0.4 pmol/liter, p = NS) 1 to 1.5 h after the last dose of L-arginine. 
Conclusions. In these healthy young adult men, oral L-arginine 
inhibited platelet aggregation by way of the nitric oxide pathway. 
However, it had no effect on systemic hemodynamic variables, 
plasma nitrosylated protein levels or endothelium-dependent di- 
lation. Therefore, at certain doses, oral L-arginine may result in a 
relatively platelet.specific ncrease in nitric oxide production. 
(J Am CoU Cardiol 1995;26:1054-61) 
L-Arginine is the physiologic substrate for nitric oxide synthesis 
(1). Nitric oxide is an important vascular mediator and may be 
released by endothelial cells (leading to vasorelaxation) and by 
platelets (leading to inhibition of aggregation) (2-5). It is released 
continuously from vascular endothelium inthe basal state (6), and 
its secretion may be enhanced in response to many physical (e.g., 
shear stress) or chemical (e.g., acetylcholine) stimuli (7,8). Its 
effects on target cells in the vascular system usually occur through 
activation of guanylate cyclase and an increase in intracellular 
cyclic guanosine monophosphate (GMP) (9). 
Nitric oxide has been shown to possess everal antiathero- 
genic properties (10). In cholesterol-fed rabbits, oral L-arginine 
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results in improved endothelium-dependent dilation, de- 
creased monocyte adherence to endothelium, decreased plate- 
let aggregation to adenosine diphosphate (ADP) and reduced 
atheroma formation (11-13) through activation of the nitric 
oxide/cyclic GMP pathway. In hypercholesterolemic humans, 
L-arginine given intravenously improves endothelium- 
dependent dilation immediately, although in normocholester- 
olemic animals and humans, c-arginine may not enhance 
endothelial nitric oxide production above baseline levels (14- 
16). However, the vascular effects of oral L-arginine have not 
been studied in humans. We hypothesized that oral supple- 
mentation with c-arginine in healthy subjects may increase 
nitric oxide synthesis in endothelial cells and in platelets, 
thereby influencing endothelium-dependent vasodilation and 
platelet aggregation. Using a prospective, randomized, ouble- 
blind, crossover trial design, we assessed the effect of short- 
term oral L-arginine on platelet and endothelial physiology in 
12 healthy oung adult men. 
Methods  
Subjects. Twelve men aged 27 to 37 years (mean _+ SEM 
34 _+ 1 years) were studied. Subjects were included if they had 
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no known vascular isk factors; none had symptoms or signs of 
hypertension, diabetes mellitus, clinically apparent vascular 
disease, hyperlipidemia or family history of premature athero- 
sclerosis. All were lifelong nonsmokers. For the duration of the 
study the subjects were asked to avoid all oral or topical 
medications and large quantities of alcohol, onions or garlic 
(which may interfere with platelct function). This study was 
approved by the institutional ethics committee, and each 
subject gave written informed consent. 
Experimental protocol. Each subject was seen on three 
occasions: at baseline, after 3 days of oral L-arginine and after 
3 days of placebo (administered in random order). At each visit 
blood was taken for determination of fasting plasma lipids 
(total cholesterol, triglycerides and high density lipoprotein 
[HDL] cholesterol), serum arginine and urea levels, liver 
function tests, an assay of plasma nitrosoprotein level and 
platelet aggregometry. Heart rate, blood pressure and 
endothelium-dependent dilation in the brachial artery were 
then measured, as described later. 
After baseline tests, the subjects were randomly assigned to 
receive ither placebo r L-arginine powder (Scientific Hospi- 
tal Supplies, Liverpool, England, United Kingdom). L-arginine 
was administered as a pineapple-flavored powder dissolved in 
water at a dose of 7 g three times daily, taken with meals, for 
3 days. Placebo powder was matched for flavor and appearance 
and did not contain any protein. There was a 7 to 14-day 
washout period between the alternate medications. Blood and 
hemodynamic tests were performed 1 to 1.5 h after the last 
dose of each powder in each subject. 
Biochemical studies. Total cholesterol, triglycerides and 
urea levels were determined enzymatically with t e use of a 
Hitachi 747 autoanalyzer. The level of HDL cholesterol was 
measured after dextran sulfate magnesium precipitation. The 
level of low density lipoprotein (LDL) cholesterol was calcu- 
lated by using the method described by Friedwald et al. (17). 
Arginine levels were assessed with high performance liquid 
chromatography. 
Nitrosoprotein assay. Nitric oxide normally circulates in 
the plasma partially complexed to thiol groups of proteins (18), 
and nitrosoprotein levels in plasma are therefore thought o 
reflect endothelial nitric oxide production (6). However, be- 
cause other nitric oxide products, such as nitrate (19), are 
present in the circulation, no single assay can give a quantita- 
tive estimate of circulating nitric oxide; w  measured circulat- 
ing nitrosoproteins a an indicator of the endogenous plasma 
levels of bioavailable nitric oxide (18). In this study, nitroso- 
proteins were determined in freshly prepared plasma after 
displacement of nitric oxide with mercury (Hg2+), by diazoti- 
zation of sulfanilamide followed by coupling with N-(1- 
naphthyl) ethylenediamine, according to the method of Saville 
(20). Blood samples were collected into heparin on ice, imme- 
diately transported to the laboratory and centrifuged for 
20 min at 4°C to remove cells. The supernatant plasma was 
removed to a separate tube on ice and assayed immediately for 
protein-bound nitric oxide (19). Preliminary studies used ni- 
trosylated bovine serum albumin to establish the half-life of 
nitrosoproteins under the conditions of blood sampling and 
assay. No detectable oss of nitrosylated bovine serum albumin 
in plasma was found during 2 h of storage at room tempera- 
ture. Standard curves were produced by using sodium nitrite 
(linear, r > 0.99 in all c ses). Control incubations in which 
Hg 2+ was omitted indicated that plasma free nitrite levels were 
below the limits of detection of the assay. Triplicate determi- 
nations of nitrosoproteins on a single batch of plasma, assayed 
on the same day, gave standard eviations of <5%. 
Platelet aggregometry. Platelet aggregation was assessed 
by measuring the change in absorbance ofplatelet-rich plasma, 
which occurs as platelets aggregate, as described elsewhere 
(21). Platelet-rich plasma was prepared from citrated venous 
blood by slow centrifugation (150 g for 5 min at room 
temperature). Platelet-poor plasma was then prepared by 
centrifugation at 1,600 g for 10 rain. The platelet count was 
standardized to200 to 400 x 109/liter, and 30 min was allowed 
for recovery before the agonists were added and the optic 
absorbance measured. Platelet-rich plasma was used to set the 
0% transmission and platelet-poor plasma to set the 100% 
transmission. Platelet aggregation was assessed in response to 
2/zmol/liter of ADP and 5 p, mol/liter of epinephrine. 
One month after completion of the double-blind phase of 
the study, blood from 8 of the 10 subjects who had normal 
baseline platelet aggregation was tested further, in vitro (the 
other 2 subjects were no longer available). Platelet-rich plasma 
was prepared, and the aggregation response to 2 p~mol/liter of 
ADP was measured after 20 min incubation with L-arginine 
(400; 600; and 800 or 1,000 [or both] /~mol/liter) (Sigma 
Diagnostics). The response to similar volumes of the diluent, 
phosphate-buffered saline solution was normal in every case. 
The lowest dose at which inhibition was observed was 
recorded, and then the platelet-rich plasma was incubated 
for 20 min with the same concentration of D-arginine 
(Calbiochem-Novabiochem). Finally, platelet-rich plasma was 
preincubated for 20 min with N-monomethyl-L-arginine (300 
txmoi/liter), a specific nitric oxide synthase inhibitor (Calbio- 
chem-Novabiochem), followed by 20 rain of exposure to L- 
arginine. Again, the response to similar volumes of phosphate- 
buffered saline solution for the same incubation times was 
normal. 
Finally, six of the study subjects had 3 further days of oral 
L-arginine supplementation (7 g three times daily), including 
four men who had had profound inhibition of ADP-induced 
platelet aggregation after oral L-arginine in the crossover phase 
of the trial and two men who had had no change in platelet 
function. In each case, the subject's response to oral L-arginine, 
in terms of change in both plasma L-arginine and platelet 
aggregation, was almost identical to that seen previously. 
ADP-induced platelet aggregation was measured as before, 
with and without ex vivo addition of 300 /~mol/liter of N- 
monomethyl-L-arginine for 15 min, and levels of platelet cyclic 
GMP were also determined, both at baseline and after the final 
dose of oral L-arginine. 
Platelet cyclic GMP determinations. The method for prep- 
aration of platelet extracts for cyclic GMP assay was similar to 
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that described by Groves et al. (22). After determination f 
platelet count, duplicate aliquots of platelet-rich plasma were 
centrifuged at2,500g for 10 rain at room temperature, and the 
plasma was removed. No aggregating agent was used. The 
platelet pellet was dispersed by vortexing and 1 ml of 6% 
trichloroacetic acid was added. The mixture was vortexed 
vigorously before centrifugation at 2,500 g for 10 rain. The 
supernatant was removed and extracted four times with an 
equal volume of water-saturated ether. The aqueous phase was 
stored frozen at -20°C. Cyclic GMP was determined after 
acetylation by radioimmunoassay (Amersham); all samples 
were assayed in duplicate in a single batch. 
Hemodynamic variables. At each visit, blood pressure and 
heart rate were measured three times at 2-rain intervals, with 
the subject in a fasting state after at least 10 rain of supine rest 
in a temperature-controlled room, and the results were aver- 
aged. 
Brachial artery vascular reactivity. Endothelial function 
was assessed noninvasively by measuring endothelium- 
dependent dilation, as described previously (23). High resolu- 
tion external ultrasound (128XP/I 0 with 7.0-MHz linear array 
transducer, Acuson), was used to measure changes in brachial 
artery diameter in response to reactive hyperemia nd to 
nitroglycerin. The right brachial rtery was scanned in longi- 
tudinal section 2 to 15 cm above the elbow (control scan) after 
the subject had >-10 rain of rest in the supine position. Depth 
and gain settings were optimized to identify the vessel wall to 
lumen interface, and a rest scan was recorded. Arterial flow 
velocity was measured at rest by pulsed wave Doppler study, 
and flow was calculated from the velocity-time integral, heart 
rate and vessel diameter (23). ttyperemia was induced by 
inflation and then deflation of a pneumatic cuff' placed around 
the forearm (below the scanned part of the arte~), inflated to 
approximately 250 mm Hg for 4.5 rain. The artery was scanned 
before cuff inflation and for 90 s after cuff deflation. In the 
intact human, flow-mediated ilation produced in this way has 
been shown (24,25) to depend on endothelial production of 
nitric oxide. Flow velocity was remcasured during the 1st 15 s 
after cuff deflation, and reactive hyperemia was calculated as 
the ratio of the postdeflation flow to the rest flow value. After 
10 min of rest a further control scan was recorded and finally 
400 ~g of nitroglycerin spray was administered. The final scan 
was performed 3 rain after nitroglycerin. All scans were 
recorded on super-VHS tape and later analyzed by two 
independent observers who did not know the identity of the 
subject, the scan sequence or the stage of the experiment. For 
calculation of flow-mediated dilation, the vessel diameter at 
60 s after cuff deflation was divided by the average control 
diameter. For each subject, the average value of the two 
observers for both flow-mediated and nitroglycerin-induced 
dilation is presented. 
Statistics. All descriptive data are expressed as mean 
value _+ SEM. To assess the day to day variability of the main 
variables measured, the differences between the baseline and 
placebo conditions were calculated for each variable for each 
subject, and the variability was expressed as the mean, SD and 
range of these differences. Next, an"order effect" related to 
treatment randomization was excluded by comparing the re- 
sults from the six subjects receiving L-arginine first with those 
from the six subjects receiving placebo first. Independent 
samples t tests howed no significant differences inthe baseline 
or the postsupplementation data between these two groups. 
Thereafter, data from each subject were assessed by using 
repeated measures analysis of variance, followed by theScheff6 
procedure for multiple comparisons. Accordingly p values in 
the Results section refer to the comparison of the results 
obtained after L-arginine with those obtained after placebo. 
Correlation coefficients between variables were calculated by 
linear regression. Statistical significance was inferred at a 
two-sided p value <0.05. 
On the basis of the low day to day variability of measure- 
ment of flow-mediated dilation that we (23,26) have previously 
documented, we calculated that if oral L-arginine had caused a
2.5% improvement in endothelium-dependent dilation over 
that obtained with placebo, a study of this sample size would 
have had 80% power to detect this change at he 0.05 
significance level (two-sided). Similarly, this study had 80% 
power to detect a 5-ram Hg decrease in systemic blood 
pressure if L-arginine had a significant hypotensive effect. 
Resu l ts  
~-Arginine was well tolerated at the dose given, and all 
subjects reported compliance with every dose. One subject had 
mild gastrointestinal symptoms (abdominal bloating) and an- 
other experienced mild headaches while taking L-arginine. One 
subject had mild gastrointestinal symptoms while taking pla- 
cebo. The results are summarized in Table 1. 
Repeatability. Placebo values were similar to baseline val- 
ues for all variables measured. For nitrosoprotein levels, the 
day to day variability was 0.7 _+ 0.7 (range 0 to 2.7) ~mol/liter, 
for mean blood pressure 7 _+ 4 (range 1 to 13) mm Hg, for rest 
vessel size (i.18 + 0.11 (range 0.01 to 0.39) ram, for flow- 
mediated ilation 1.1 _+ 0.7% (range 0.4% to 2.8%) and for 
ADP percent aggregation 3.4 _+ 3.2% (range 0 to 10%). 
Lipid studies. At baseline, the mean total cholesterol level 
was 210 _+ 9 rag/all, low density lipoprotein (LDL) cholesterol 
168 _+ 12 mg/dl, HDL cholesterol 43 _+ 4 mg/dl and triglycer- 
ides 124 + 12 mg/dl. All lipid values were similar after placebo 
and after L-arginine therapy. 
Biochemical studies. With L-arginine supplementation 
there was a rise in plasma levels of arginine and urea but no 
change in liver function tests. Arginine levels were 128 _+ 12 
~tmol/liter after placebo and 303 _+ 36 t~mol/liter after e- 
arginine (p = 0.01). Urea levels were 5.2 _+ 0.2 mmol/liter after 
placebo and 6.7 _+ 0.4 mmol/liter after e-arginine (p < 0.01). 
Nitrosoproteins. There was no significant change in plasma 
nitrosoprotein concentration; levels were 3.3 + 0.4 ~mol/liter 
after placebo and 3.5 _+ 0.5/~mol/liter after L-arginine supple- 
mentation. 
Platelet studies. Results of platelet aggregometry were 
reproducibly abnormal in two subjects at baseline (with ira- 
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Table 1. Biochemical, Hemodynamic and Platelet Variables Measured 
at Baseline and After 3 Days of L-Arginine and 3 Days of Placebo 
Therapy (administered orally in random order) in 12 Young Men 
Baseline L-Arginine Placebo 
L-Arginine (~mol/liter) 129 _+ 10 303 _+ 36* 128 _+ 12 
Urea (mmol/liter) 5.7 _+ (}.2 6.7 + 0.4* 5.2 _+ 0.2 
Cholesterol (mg/dl) 210 ± 9 212 + 8 214 _+ 8 
LDL cholesterol (mg/dl) 168 + 12 171 _+ 8 167 _+ 9 
HDL cholesterol (mg/dl) 43 ± 4 47 _+ 4 43 : 4 
Triglycerides (mg/dl) 124 + 12 133 +_ 24 142 _+ 26 
NO proteins (tzmol/liter) 4.2 + 0.5 3.5 ± 0.5 3.3 ± 0.4 
Blood pressure (ram Hg) 117/76 +_ 3/2 111/76 _+ 2/2 112/78 * 3/2 
Heart rate (beats/min) 65 _+ 3 68 + 3 73 = 3 
Vessel size (ram) 4.27 _+ ILl 4.27 ÷ 0.1 4.3(l = 0.1 
Flow-mediated dilation (%) 5.8 : 11.7 6.1 + 0.7 6.5 _+ 0.66 
Nitroglycerin (%) 15.1 ± 11.9 17 ~ 1.2 15 : 0.9 
ADP aggregation (%)¢ 79.3 _+ 2.6 37.4 ± 11.5' 80.5 : 2.5 
Epinephrine 79 : 2.1 69.8 : 7.6 77.8 : 3.2 
aggregation (fC)~ 
*p -< 0.02 versus placebo, tn - 10 for the platelet aggregation tests. All data 
are expressed as mean value _+ SEM. ADP - adenosine diphosphate; HDL = 
high densiW lipoprotein; LDL = low density lipoprotein; NO = nitric oxide. 
paired aggregation in response to ADP and epinephrine, 
<60% aggregation to each), and therefore the effect of 
L-arginine and placebo on platelet aggregation was only mea- 
sured in those 10 subjects with normal platelet function. 
Platelet aggregation was impaired in response to ADP in 7 of 
10 subjects after L-arginine supplementation (Fig. 1). The 
percent aggregation i duced by ADP was 80.5 + 2.5% after 
placebo and 37.4 + 11.5 after L-arginine supplementation (p = 
0.02, n = 10). The degree of inhibition of platelet aggregation 
in response to ADP after L-arginine was correlated with the 
plasma arginine level at the same time (r = 0.74, p = 0.01), and
two of the three "nonresponders" had no increase in plasma 
arginine levels above th  normal range (120 to 200 ~zmol/liter) 
(Fig. 2). In contrast, there was no correlation between the 
degree of platelet inhibition and the plasma urea level after 
L-arginine (r = -0.16, p = 0.64). There was also no correlation 
Figure 1. Effect of oral L-arginine and placebo n platelet aggregation 
(%) in response toadenosine diphosphate (ADP). Platelet aggregation 
was significantly inhibited by L-arginine (p = 0.02). 
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between cholesterol level and either baseline platelet aggrega- 
tion (r = 0.05, p = 0.89) or change in aggregation after oral 
L-arginine (r = 0.12, p = 0.74). Aggregation i response to 
epinephrine was mildly but not significantly impaired after 
L-arginine; 77.8 _+ 3.2% after placebo and 69.8 _+ 7.6% after 
L-arginine (p = 0.31). Therefore the e-arginine-induced im-
pairment of the platelet aggregation response was noted when 
2 gmol/liter of ADP but not 5 gmol/liter of epinephrine was 
used as the agonist; this observation is consistent with a 
moderate rather than a more severe defect in the aggregation 
pathway. 
In four subjects in whom ADP-induced platelet aggregation 
was markedly impaired after oral L-arginine, this effect was 
completely reversed in three subjects and partially reversed in 
one subject by ex vivo incubation with N-monomethyk- 
arginine, whereas N-monomethyl-L-arginine had no effect on 
platelet aggregation at baseline (baseline aggregation 74%, 
70%, 70% and 64%; baseline with N-monomethyl-L-arginine 
70%, 73%, 65% and 62%; post L-arginine 3%, 48%, 3% and 
11%; post L-arginine with N-monomethyl-t-arginine 72%, 
68%, 66% and 24%). Furthermore, platelet cyclic GMP levels 
were higher after than before oral L-arginine therapy (1.91 _+ 
0.46 vs. 1.38 _+ 0.40 pmol/109 platelets, p = 0.04). In contrast, 
in two subjects whose platelets were not affected after oral 
L-arginine, and who had only small increases in plasma L- 
arginine after supplementation, ex vivo incubation with N- 
monomethyl-L-arginine had no effect on platelet aggregation 
either before or after L-arginine therapy, and platelet cyclic 
GMP levels were also unchanged. To explore the source of 
nitric oxide affecting platelet aggregation, the in vitro response 
of platelet-rich plasma to L- and D-arginine was measured. In
vitro, platelet aggregation in response to ADP was inhibited by 
600 ~tmol/liter of L-arginine in five of eight subjects tested 
(37.2 + 4.0% with L-arginine vs. 72.0 _+ 3.4% with phosphate- 
buffered saline solution, the control solution, p = 0.002), 
inhibited by 800 /~mol/liter (but not 600 /zmol/liter) of L- 
arginine in one subject (44% vs. 80%) and normal in the two 
other subjects despite incubation with 1,000 tzmol/liter of 
L-arginine. In the six subjects in whom L-arginine (600 to 800 
txmol/liter) resulted in impaired aggregation, D-arginine at 
similar concentrations had no detectable effect (70.3 + 3.1%, 
p = 0.45 vs. control value). Preincubation of platelets with 
N-monomethyl-L-arginine pr vented the e-arginine-mediated 
inhibition of platelet aggregation (70.5 + 5.2%, p = 0.55, n = 
4). These data suggest hat L-arginine enhances nitric oxide 
production by platelets or leukocytes, or both. 
Hemodynamie measurements. No change occured in blood 
pressure or heart rate after either placebo or L-arginine 
supplementation (Table 1). 
Vascular reactivity studies. No significant change was seen 
in the vascular reactivity studies with either L-arginine supple- 
mentation or placebo. Vessel size was similar after placebo and 
L-arginine supplementation (4.3 _+ 0.1 mm vs. 4.27 _+ 0.1 ram). 
Rest blood flow in the brachial artery was 83 _+ 7 ml/min after 
placebo and 100 _+ 8 ml/min after L-arginine supplementation, 
and the degree of reactive hyperemia after cuff deflation was 
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Figure 2. The degree of inhibition of platelet aggregation 
(percent decrease in adenosine diphosphate [ADP] response) 
was correlated with the level of serum arginine obtained after 
3 days of oral k-arginine supplementation. 
413 _+ 94% after placebo and 445 + 105% after k-arginine. 
Flow-mediated dilation was 6.5 + 0.7~k after placebo and 
6.1 _+ 0.7% after k-arginine (p : NS). There was no correlation 
between cholesterol level and cithcr baseline flow-mediated 
dilation, or change in dilation after oral L-arginine (p> 0.60 in 
each case). With nitroglycerin administration there was 15.0 + 
0.9% dilation after placebo and 17 +_ 1.2% dilation after 
L-arginine supplementation. 
Discuss ion  
Our study demonstrates that in hcalthy oung adult men, 
oral L-arginine therapy results in inhibition f platelet aggre- 
gation by way of the nitric oxide pathway. In contrast, no effect 
was observed on rest blood pressure, endothelium-dependent 
dilation or plasma levels of nitrosoproteins, suggesting that 
L-arginine may not be a rate-limiting substrate in the 
production of endothelium-derived nitric oxide by the 
healthy vessel wall. 
The effects of oral L-argininc on platelet and endothelial 
physiology have not previously been reported in humans. The 
significant inhibition f platelet aggregation related to L- 
arginine therapy in this study is almost certainly mediated 
through the nitric oxide/cyclic GMP pathway. In 1981, Mellion 
et al. (27) first showed in vitro hat nitric oxide donors, such as 
nitroprusside, increased platelet cyclic GMP levels and thereby 
caused inhibition of platelet aggregation. Nitric oxide has also 
been shown to inhibit platelet adhesion and aggregation, under 
flow conditions, in vitro (28) and in experimental animals (29). 
Recently Tsao et al. (13) also showed that oral k-arginine 
attenuated platelet reactivity in hypercholesterolemic rabbits 
by way of the nitric oxide/cyclic GMP pathway. In other animal 
studies, substance P andacetylcholine treatment ofarteries has 
resulted in nitric oxide release by the endothelium, and 
subsequent increases in platelet cyclic GMP with inhibition of 
platelet aggregation (30,31). In human subjects, molsidomine, 
a nitric oxide donor, has also been shown to modulate 
platelet physiology (32), as has intravenous c-arginine, in 
high doses (33). 
Platelet effects. In our study, oral L-arginine inhibited 
platelet aggregation to ADP, and the degree of platelet 
inhibition depended on the plasma levels of c-arginine 
achieved in vivo (Fig. 2). The variability in plasma e-arginine 
levels after supplementation observed was most likely due to 
intra-individual variations in absorption or metabolism of 
the oral c-arginine powder. The significant inhibition of 
platelet aggregation observed after L-arginine was reversible 
with N-monomethyl-L-arginine, a specific nitric oxide syn- 
thase inhibitor, and it was associated with a rise in platelet 
cyclic GMP levels. Furthermore, the c-arginine-related 
platclet abnormality could be reproduced in vitro by e- but 
not by D-arginine, and it could be prevented by preincuba- 
tion with N-monomethyl-L-arginine. These data suggests 
that the effect of c-arginine on platelet physiology is medi- 
ated through the production of nitric oxide. Faint et al. (34) 
have shown that both whole blood and platelet aggregation 
are inhibited in vitro by L-arginine, and these data together 
with our in vitro results uggest that synthesis of nitric oxide 
from c-arginine may take place in platelets or leukocytes, or 
both. Platelets are known to contain nitric oxide synthase 
(35). In this study, the concentrations of L-arginine (600 to 
800 txmol/liter) required to produce impaired platelet activ- 
ity were higher than the plasma levels (200 to 500 /~mol/ 
iter) achieved in vivo. Possible xplanations include that the 
L-arginine levels were raised for days in vivo rather than for 
minutes in vitro, that the intraplatelet concentration of 
L-arginine may have been higher than the plasma levels, or 
thatin vivo, nitric oxide released from other nonblood cells, 
such as endothelial cells, may be transported into platelets 
and enhance the anti-aggregatory effect. This latter possi- 
bility, that endothelium-derived nitric oxide may be contrib- 
uting to the t,-arginine-related platelet defect, is unlikely in 
this study, as other measures of endothelium-derived nitric 
oxide such as nitrosoprotein levels, hemodynamic variables 
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and the vascular reactivity were not changed during L- 
arginine therapy. 
In experimental studies, it has not been possible to separate 
the antiplatelet action of nitric oxide donors from the ffects on 
vascular tone, and this inability has limited the use of nitric 
oxide donors solely as inhibitors of platelet activation (36). 
However, in this study of healthy oung adult men, L-arginine 
appears to have acted as a platelet-selective nitric oxide d nor.
Because e-arginine is a naturally occurring amino acid that 
appears to have an acceptable side effect profile, its use as a 
clinically applicable antiplatelet agent may warrant further 
investigation. 
Endothelial effects. In cholesterol-fed rabbits, oral L- 
arginine has a variety of effects on vascular endothelium, 
including decreased adherence of monocytes to endothe- 
lium and preservation of endothelium-dependent ilation to 
acetylcholine (11,12). In the rabbit model, oral L-arginine 
inhibits atheroma formation (11). The effects of parenteral 
L-arginine have also been studied in hypercholesterolemic 
humans. Creager et al. (14) demonstrated that pretreatment 
with intravenous L-arginine improves the endothelium- 
dependent vasodilator response to acetylcholine in hyper- 
cholesterolemic humans (14). Drexler et al. (16) found 
similar improvements in the coronary circulation. In both of 
those studies, however, L-arginine had no effect on endo- 
thelium-dependent dilation in normocholesterolemic con- 
trol subjects, uggesting that L-arginine was not rate-limiting 
for nitric oxide production i  normal persons. Similarly, oral 
L-arginine had neither a consistent or a significant vascular 
effect in our 12 subjects, who had no evidence of severe or 
familial hypercholesterolemia or ny other known risk fac- 
tors for vascular disease. Oral L-arginine had no significant 
effect on rest blood pressure, vessel size, baseline blood flow 
or response to hyperemia, or endothelium-dependent or 
smooth muscle-dependent vasodilation. Very high dose 
intravenous e-arginine (up to 30 g in 30 min) has been 
shown (37) to produce hypotension n normotensive hu- 
mans; however, vasodilation isalso produced by intravenous 
D-arginine at these high doses (38), and therefore this effect 
may not be mediated through nitric oxide. 
Limitations of the study. Although only one aspect of 
platelet physiology was assessed (platelet aggregation), this 
test has been shown to be sensitive to the presence of 
increased levels of nitric oxide in platelets (25,28-30). In 
contrast, three variables were measured to assess whether 
endothelial production of nitric oxide was increased by oral 
L-arginine therapy: flow-mediated dilation, systemic hemo- 
dynamics and plasma nitrosoprotein levels. Flow-mediated 
dilation of arteries is dependent on endothelium-derived 
nitric oxide (8), and it is abnormal not only in atheroscle- 
rotic arteries (39) but also in vessels of asymptomatic 
subjects with risk factors for atherosclerosis (40,41). 
Acetylcholine- induced changes in endothelium-derived ni- 
tric oxide production may be a more sensitive marker of 
early vascular damage than flow-induced changes (42); 
however, the latter measurement is more physiologically 
relevant and can be measured noninvasively, facilitating 
serial study of endothelial function (23,24). Rest blood 
pressure and vessel tone are also controlled by endothelium- 
derived nitric oxide (6,43), and they might have changed if
L-arginine therapy had resulted in a large increase in nitric 
oxide production by the vascular endothelium. Finally, the 
sensitivity of nitrosoprotein levels to changes in endothelial 
production of nitric oxide is not well known, although 
Stamler et al. (6) recently demonstrated that plasma nitroso- 
protein levels in humans decrease dramatically after sys- 
temic administration of N-monomethyl-L-arginine a dsug- 
gested that nitrosoprotein levels may be useful to detect 
alterations in the activity of endothelial nitric oxide produc- 
tion in vivo. Thus, although plasma nitrosoproteins may not 
reflect he total nitric oxide output in vivo (19), they may be 
considered a useful indicator of endothelial nitric oxide 
synthesis. Whether other endothelial functions apart from 
nitric oxide production were altered by L-arginine therapy 
was not assessed in our trial. 
Our study had good power to detect small changes in 
either blood pressure or endothelium-dependent dilation, 
and the day to day variability in flow-mediated dilation in 
this study was similar to that previously reported (23,24). 
Possible explanations for this negative finding include that 
too little L-arginine was given; the plasma levels achieved 
were much lower than in studies in which L-arginine was 
administered intravenously (14,16). The dose of oral L- 
arginine chosen in this trial (7 g, three times daily) was 
approximately equivalent to the dose given to cholesterol- 
fed rabbits to produce antiatherogenic effects, calculated on 
a weight for weight basis (11), and it is approximately four 
times greater than the normal daily arginine intake in 
humans (44). Furthermore this oral dose is known to be 
safe, as similar doses are used long term in children and 
young adults with inborn errors of metabolism, such as 
citrullinemia (45). It would be impractical to give a higher or 
more frequent oral dose than the one used in our study 
because of the large amount of powder in each dose and the 
three times daily dosage schedule. It is also possible that 
the increased plasma L-arginine was not being taken up by 
the endothelial cells (35). However, the most likely expla- 
nation is that normal endothelium, which already secretes 
nitric oxide in the basal state (6), does not normally produce 
significantly more nitric oxide even if extra substrate is 
available. Intravascular L-arginine does not increase ndo- 
thelial nitric oxide production i  the normal pulmonary (15) 
or systemic irculations (14,16), and the dissociation con- 
stant of endothelial nitric oxide synthase for e-arginine 
(obtained in cell free experiments) uggests that substrate 
availability might not be rate limiting (46). In more severe 
hypercholesterolemia where nitric oxide may be catabolized 
at an increased rate, possibly by extracellular f ee radicals 
(47), provision of excess L-arginine may be expected to 
improve endothelium-dependent dilation, and studies to 
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evaluate the effect of oral L-arginine on vascular physiology 
in patients with preexisting endothelial dysfunction are 
therefore currently underway in our laboratory. 
Conclusions. In healthy oung adult men, oral L-arginine 
may increase intracellular production of nitric oxide in plate- 
lets, resulting in inhibition of their physiologic activation 
pathways. However, because no effects were observed on rest 
blood pressure, nitrosoprotein levels or endothelium- 
dependent dilation, L-arginine may not significantly enhance 
nitric oxide production by normal endothelial cells. It is 
therefore possible that at certain doses, oral L-arginine may 
result in a relatively platelet-specific increase in nitric oxide 
production. 
We thank Margaret Nelson, Paul Losco and Robyn McCredie for technical 
assistance. 
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